Navigation Links
Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced two presentations of data for two new potential applications in oncology of its novel agonists of Toll-like receptor 9 (TLR9) at the Annual Meeting of the American Association for Cancer Research (AACR) being held in Los Angeles, CA, April 14-18, 2007. The first presentation covered a preclinical study in which Idera's lead oncology candidate, IMO-2055, in combination with the multikinase inhibitor sorafenib, showed enhanced antitumor activity compared to either agent alone in a mouse xenograft model. The second presentation covered a preclinical study in which an analog of IMO-2055 optimized for mice was administered by the intranasal route and showed potent antitumor activity in mouse models of lung metastases of colon carcinoma and melanoma.

"The new data in a mouse model show IMO-2055 has additive antitumor activity with sorafenib, and adds to our previous data of additive antitumor activity by IMO-2055 observed in combination with other targeted agents such as VEGF and EGFR inhibitors," said Robert W. Karr, M.D., President of Idera. "Our new data on intranasal delivery show promise for a potential new route of administration specifically to treat lung tumors."

Abstract 4771 entitled, "The combination of IMO-2055, a synthetic agonist of toll-like receptor-9 (TLR9), and the multikinase inhibitor sorafenib tosylate (Nexavar(R)) demonstrates enhanced antitumor activity in a human non-small cell lung cancer xenograft model," was presented by Bernardo Chavira of TGen Drug Development Services in the session Cancer Therapeutics 2. The combination of IMO-2055 and sorafenib in the study lead to increased antitumor effects and increased survival, with survival means of 30.0 days in the IMO-2055 group, 27.8 days in the sorafenib group and 41.3 days in the combination group (P less than 0.001 compared with
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... breakthroughs in brain,research and technology may have a great ... to scientists visiting the US Senate today. At the,invitation ... Pensions,(HELP) researchers from Posit Science, a leading provider of ... lecture and,part hands-on science fair., "Many believe that ...
... Society Of Clinical Psychopharmacology ... Meeting, ... Assignee of the assets of Spherics, Inc. ("Spherics") for,the benefit of creditors, ... a sealed bid auction on October 10,2008., Topamax(R) produces adverse effects ...
Cached Medicine Technology:Senate Told Brain Technology Can Impact Public Policy 2Senate Told Brain Technology Can Impact Public Policy 3Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R) 2
(Date:7/10/2014)... is one of the top public health concerns in ... 2-19 classified as obese as of 2012. As health ... have taken to Twitter to discuss the problem. , ... assistant professor at the Brown School at Washington University ... #childhoodobesity in tweets to track Twitter conversations about the ...
(Date:7/10/2014)... medical imaging far outweigh the risks when children receive ... Right Radiation Dose. However, overuse and misuse of imaging ... a collaborative effort to ensure a national protocol is ... Journal of Patient Safety , calls for the ... Accreditation Commission, and the Centers for Medicare & Medicaid ...
(Date:7/10/2014)... Harbor, NY For decades, health-conscious people around the ... in antioxidants, figuring this was one of the paths ... , Yet clinical trials of antioxidant supplements have repeatedly ... to reduce their cancer risk. Virtually all such ... cancer. In fact, in several trials antioxidant supplementation ...
(Date:7/10/2014)... Men who experience hot flashes are unlikely to ... from their silent suffering if they are willing ... a Baylor University case study., After seven weeks of ... hot flashes following prostate cancer surgery showed a drastic ... impressive improvement in sleep quality, according to the study., ...
(Date:7/9/2014)... a small increased risk of prostate cancer, and a ... to a new study from Harvard School of Public ... even among men who received regular PSA screening, suggesting ... by diagnostic bias. It is the largest and most ... between vasectomy and prostate cancer. , The study appears ...
Breaking Medicine News(10 mins):Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Vasectomy may increase risk of aggressive prostate cancer 2
... /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: ... in the People,s Republic,of China, held a Board ... which a new,Board member was appointed to serve ... an Audit Committee and a Compensation Committee were ...
... 23 Laura Kolkman, President,Mosaica Partners, a ... been selected to serve as Chair of ... Healthcare Information,Exchange (HIE) Steering Committee., The ... all HIE,stakeholders including providers, payers, vendors, consultants ...
... new survey of employers by the,non-profit Midwest Business Group ... the Smoke-free Illinois Act*, helps companies and,their employees overcome ... a challenge., MBGH conducted its second annual Smoking ... level of employer involvement in reducing tobacco,use among workers. ...
... up on innuendo and social cues is a central component ... to determine another person,s intentions in a social interaction. New ... mechanisms that are responsible for such social difficulties in autism, ... all of us. , According to the study, which ...
... by Edison Pharma , ... Boston (PRWEB) July 23, ... Guide to MITO Management, a comprehensive online resource designed to assist ... affected by mitochondrial disease. The Clinicians Symptom Guide to MITO Management ...
... of free web meeting software has recently added advanced features like shared ... far, these features were only available for a high cost with paid ... Desktop Service, which lets you log into your home or office PC ... ...
Cached Medicine News:Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2Health News:Stopping Smoking in the Workplace Continues to Be a Challenge 2Health News:Stopping Smoking in the Workplace Continues to Be a Challenge 3Health News:Autism's social struggles due to disrupted communication networks in brain 2Health News:MitoAction Develops On-Line Resource for Mitochondrial Disease Care Providers 2Health News:How to Conduct Free Web Meetings and Remote Desktop? 2
... Cardiology specific EMR / PM system ... nationwide,enabling more effective patient care decisions.,AcerMed's ... clinicians with critical information on a ... care.,Our Cardiology specific clinical pathways have ...
... in Critical Care & Emergency Medicine. ... cordless, and simple to use device which ... of the pupillary light reflex (PLR). Now ... which are not discernable to the naked ...
... Metrikas pager-sized A1cNow ... technology to provide healthcare ... access to quantitative A1C ... indicator of diabetes management ...
... VenaCure Laser Vein Treatment. It is estimated ... worldwide have varicose veins. In the United States, ... of 60 suffer from painful and unsightly venous ... the capabilities of vascular therapy for the treatment ...
Medicine Products: